Atsushi Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atsushi Ishii has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Shinichi Hirose
General Medical Research Center School of Medicine, Fukuoka University, 45-1 7-chome Nanakuma Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan
13 shared publications Shinichi Hirose
Department of Pediatrics, Fukuoka University School of Medicine, Japan
4 shared publications- Aaron Ramonett
Department of Pharmacology, University of Arizona
2 shared publications - Akihisa Okumura
Department of Pediatrics, Aichi Medical University, Japan
2 shared publications - Ayako Goto
Department of Pediatrics, Fukuoka University School of Medicine, Fukuoka, Japan
2 shared publications - Christopher Cartmell
Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (47)
ATAT1-dependent microtubule acetylation drives pancreatic tumorigenesis through DNMT1-mediated regulation of NDRG4
Microtubule (MT) acetylation is frequently elevated in cancer and associated with poor prognosis. Alpha-tubulin acetyltransferase 1 (ATAT1), the principal enzyme responsible for this modification, has therefore emerged as a potential therapeutic target. However, which cancer types depend on ATAT1 activity and are selectively vulnerable to its inhibition remains unclear. Here, using a phospho-specific marker of ATAT1 activity, we identify pancreatic ductal adenocarcinoma (PDAC) as an ATAT1-dependent malignancy. ATAT1 activity is elevated in human PDAC and genetically engineered mouse models, emerging during pancreatic intraepithelial neoplasia and persisting in a substantial subset of tumors. Genetic inactivation or pharmacologic inhibition of ATAT1 suppresses PDAC cell growth, reduces orthotopic tumor burden, and markedly inhibits tumor initiation in KPC mice without overt toxicity. Mechanistically, ATAT1-dependent MT acetylation sustains Akt signaling, resulting in inhibitory phosphorylation of GSK3β and stabilization of the DNA methyltransferase DNA methyltransferase 1 (DNMT1). Elevated DNMT1 promotes repression of tumor suppressor genes, including NDRG4, whereas inhibition of ATAT1 or DNMT1 restores NDRG4 expression and impairs tumor growth. Together, these findings identify a previously unrecognized ATAT1-Akt-GSK3β-DNMT1 signaling axis linking cytoskeletal acetylation to NDRG4 repression and reveal ATAT1 as a therapeutic vulnerability during the early stages of pancreatic tumorigenesis.
- 18 November 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (47)
Open AccessATAT1-dependent microtubule acetylation drives pancreatic tumorigenesis through DNMT1-mediated regulation of NDRG4
Microtubule (MT) acetylation is frequently elevated in cancer and associated with poor prognosis. Alpha-tubulin acetyltransferase 1 (ATAT1), the principal enzyme responsible for this modification, has therefore emerged as a potential therapeutic target. However, which cancer types depend on ATAT1 activity and are selectively vulnerable to its inhibition remains unclear. Here, using a phospho-specific marker of ATAT1 activity, we identify pancreatic ductal adenocarcinoma (PDAC) as an ATAT1-dependent malignancy. ATAT1 activity is elevated in human PDAC and genetically engineered mouse models, emerging during pancreatic intraepithelial neoplasia and persisting in a substantial subset of tumors. Genetic inactivation or pharmacologic inhibition of ATAT1 suppresses PDAC cell growth, reduces orthotopic tumor burden, and markedly inhibits tumor initiation in KPC mice without overt toxicity. Mechanistically, ATAT1-dependent MT acetylation sustains Akt signaling, resulting in inhibitory phosphorylation of GSK3β and stabilization of the DNA methyltransferase DNA methyltransferase 1 (DNMT1). Elevated DNMT1 promotes repression of tumor suppressor genes, including NDRG4, whereas inhibition of ATAT1 or DNMT1 restores NDRG4 expression and impairs tumor growth. Together, these findings identify a previously unrecognized ATAT1-Akt-GSK3β-DNMT1 signaling axis linking cytoskeletal acetylation to NDRG4 repression and reveal ATAT1 as a therapeutic vulnerability during the early stages of pancreatic tumorigenesis.
- 1 February 2022
- Published by Elsevier in Brain and Development
- Vol. 44 (5) , 319-328
The effectiveness of intravenous benzodiazepine for status epilepticus in Dravet syndrome
- 1 February 2022
- Published by Elsevier in Brain and Development
- Vol. 44 (5) , 319-328
The effectiveness of intravenous benzodiazepine for status epilepticus in Dravet syndrome
- Open Access
- 2 December 2020
- Published by Springer Nature in Journal of Human Genetics
- Vol. 66 (6) , 569-578
Comparative characterization of PCDH19 missense and truncating variants in PCDH19-related epilepsy
Missense and truncating variants in protocadherin 19 (PCDH19) cause PCDH19-related epilepsy. In this study, we aimed to investigate variations in distributional characteristics and the clinical implications of variant type in PCDH19-related epilepsy. We comprehensively collected PCDH19 missense and truncating variants from the literature and by sequencing six exons and intron–exon boundaries of PCDH19 in our cohort. We investigated the distribution of each type of variant using the cumulative distribution function and tested for associations between variant types and phenotypes. The distribution of missense variants in patients was clearly different from that of healthy individuals and was uniform throughout the extracellular cadherin (EC) domain, which consisted of six highly conserved domains. Truncating variants showed two types of distributions: (1) located from EC domain 1 to EC domain 4, and (2) located from EC domain 5 to the cytoplasmic domain. Furthermore, we also found that later onset seizures and milder intellectual disability occurred in patients with truncating variants located from EC domain 5 to the cytoplasmic domain compared with those of patients with other variants. Our findings provide the first evidence of two types of truncating variants in the PCDH19 gene with regard to distribution and the resulting clinical phenotype.
- 2 December 2020
- Published by Springer Nature in Journal of Human Genetics
- Vol. 66 (6) , 569-578
Open AccessComparative characterization of PCDH19 missense and truncating variants in PCDH19-related epilepsy
Missense and truncating variants in protocadherin 19 (PCDH19) cause PCDH19-related epilepsy. In this study, we aimed to investigate variations in distributional characteristics and the clinical implications of variant type in PCDH19-related epilepsy. We comprehensively collected PCDH19 missense and truncating variants from the literature and by sequencing six exons and intron–exon boundaries of PCDH19 in our cohort. We investigated the distribution of each type of variant using the cumulative distribution function and tested for associations between variant types and phenotypes. The distribution of missense variants in patients was clearly different from that of healthy individuals and was uniform throughout the extracellular cadherin (EC) domain, which consisted of six highly conserved domains. Truncating variants showed two types of distributions: (1) located from EC domain 1 to EC domain 4, and (2) located from EC domain 5 to the cytoplasmic domain. Furthermore, we also found that later onset seizures and milder intellectual disability occurred in patients with truncating variants located from EC domain 5 to the cytoplasmic domain compared with those of patients with other variants. Our findings provide the first evidence of two types of truncating variants in the PCDH19 gene with regard to distribution and the resulting clinical phenotype.
- 1 October 2020
- Published by Elsevier in Brain and Development
- Vol. 42 (9) , 686-690
Glucose transporter type 1 deficiency syndrome associated with autoantibodies to glutamate receptors
- 1 October 2020
- Published by Elsevier in Brain and Development
- Vol. 42 (9) , 686-690
Glucose transporter type 1 deficiency syndrome associated with autoantibodies to glutamate receptors
- Open Access
Neuroanatomical Considerations for Optimizing Thalamic Deep Brain Stimulation in Tourette Syndrome
Background: Deep brain stimulation (DBS) of the centromedian (CM) thalamic nucleus has reportedly been used to treat severe Tourette syndrome (TS) with promising outcomes; however, it remains unclear how DBS electrode position and stimulation parameters modulate the specific area and related networks. We aimed to evaluate the relationships between the anatomical location of stimulation fields and clinical responses including therapeutic and side effects. Methods: We collected data from eight TS patients treated with DBS. We evaluated the clinical outcomes using Yale Global Tic Severity Scale (YGTSS), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Hamilton Depression Rating Scale (HAM-D). The DBS lead location was evaluated in the normalised brain space using a 3-D atlas. The volume of tissue activated (VTA) was determined, and the associated normative connective analyses were performed to link the stimulation field with the therapeutic and side effects. Results: The mean follow-up period was 10.9 ± 3.9 months. All clinical scale showed significant significant improvement. While the VTA associated with therapeutic effects covers the CM and ventrolateral nuclei and showed association with motor networks, those associated with paraesthesia and dizziness were associated with stimulation of the ventralis caudalis and red nucleus, respectively. Depressed mood was associated with the spread of stimulation current to the mediodorsal nucleus and showed association with limbic networks. Conclusion: Our study addresses the importance of accurate implantation of DBS electrodes for obtaining standardised clinical outcomes and suggests that meticulous programming with careful monitoring of clinical symptoms may improve outcomes.
Open AccessNeuroanatomical Considerations for Optimizing Thalamic Deep Brain Stimulation in Tourette Syndrome
Background: Deep brain stimulation (DBS) of the centromedian (CM) thalamic nucleus has reportedly been used to treat severe Tourette syndrome (TS) with promising outcomes; however, it remains unclear how DBS electrode position and stimulation parameters modulate the specific area and related networks. We aimed to evaluate the relationships between the anatomical location of stimulation fields and clinical responses including therapeutic and side effects. Methods: We collected data from eight TS patients treated with DBS. We evaluated the clinical outcomes using Yale Global Tic Severity Scale (YGTSS), Yale-Brown Obsessive Compulsive Scale (Y-BOCS), and Hamilton Depression Rating Scale (HAM-D). The DBS lead location was evaluated in the normalised brain space using a 3-D atlas. The volume of tissue activated (VTA) was determined, and the associated normative connective analyses were performed to link the stimulation field with the therapeutic and side effects. Results: The mean follow-up period was 10.9 ± 3.9 months. All clinical scale showed significant significant improvement. While the VTA associated with therapeutic effects covers the CM and ventrolateral nuclei and showed association with motor networks, those associated with paraesthesia and dizziness were associated with stimulation of the ventralis caudalis and red nucleus, respectively. Depressed mood was associated with the spread of stimulation current to the mediodorsal nucleus and showed association with limbic networks. Conclusion: Our study addresses the importance of accurate implantation of DBS electrodes for obtaining standardised clinical outcomes and suggests that meticulous programming with careful monitoring of clinical symptoms may improve outcomes.
- 1 October 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 71, 1-5
PRRT2 mutations in Japanese patients with benign infantile epilepsy and paroxysmal kinesigenic dyskinesia
- 1 October 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 71, 1-5
PRRT2 mutations in Japanese patients with benign infantile epilepsy and paroxysmal kinesigenic dyskinesia
- 30 August 2019
- Published by Springer Nature in Journal of Human Genetics
- Vol. 64 (11) , 1097-1106
Copy number variation analysis in 83 children with early-onset developmental and epileptic encephalopathy after targeted resequencing of a 109-epilepsy gene panel
Early-onset developmental and epileptic encephalopathy (DEE) is a group of devastating disorders that appear during the neonatal and infantile periods. Despite great progress in the discovery of genes leading to early-onset DEE, many cases with unexplained etiology remain. Furthermore, to date, the association of copy number variations (CNVs) with early-onset DEE has seldom been addressed. Here, we investigated the contribution of CNVs to epilepsy in a cohort of Japanese children with a variety of early-onset DEEs. Single nucleotide polymorphism (SNP) array analysis was performed for 83 cases that were previously negative for pathogenic single nucleotide variants (SNVs) in 109 genes known or suspected to cause epileptic seizures. Rare CNVs were detected in a total of 12 cases (14.4%), of which three cases (3.6%) involved clearly pathogenic CNVs and nine cases (10.8%) were CNVs of uncertain significance. The three pathogenic CNVs included two de novo heterozygous deletions involving known epileptic encephalopathy genes, such as GABRG2 and PCDH19, and one maternally inherited duplication encompassing MECP2. Our findings indicate rare CNVs are also relevant for the diagnosis of early-onset DEEs, highlighting the importance of not relying only on the investigation of SNVs/small indels at the risk of missing large deletions and duplications.
- 30 August 2019
- Published by Springer Nature in Journal of Human Genetics
- Vol. 64 (11) , 1097-1106
Copy number variation analysis in 83 children with early-onset developmental and epileptic encephalopathy after targeted resequencing of a 109-epilepsy gene panel
Early-onset developmental and epileptic encephalopathy (DEE) is a group of devastating disorders that appear during the neonatal and infantile periods. Despite great progress in the discovery of genes leading to early-onset DEE, many cases with unexplained etiology remain. Furthermore, to date, the association of copy number variations (CNVs) with early-onset DEE has seldom been addressed. Here, we investigated the contribution of CNVs to epilepsy in a cohort of Japanese children with a variety of early-onset DEEs. Single nucleotide polymorphism (SNP) array analysis was performed for 83 cases that were previously negative for pathogenic single nucleotide variants (SNVs) in 109 genes known or suspected to cause epileptic seizures. Rare CNVs were detected in a total of 12 cases (14.4%), of which three cases (3.6%) involved clearly pathogenic CNVs and nine cases (10.8%) were CNVs of uncertain significance. The three pathogenic CNVs included two de novo heterozygous deletions involving known epileptic encephalopathy genes, such as GABRG2 and PCDH19, and one maternally inherited duplication encompassing MECP2. Our findings indicate rare CNVs are also relevant for the diagnosis of early-onset DEEs, highlighting the importance of not relying only on the investigation of SNVs/small indels at the risk of missing large deletions and duplications.
Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy
Objective: Pathogenic variants of KCNQ2, which encode a potassium channel subunit, cause either benign (familial) neonatal epilepsy—B(F)NE)—or KCNQ2 encephalopathy (KCNQ2 DEE). We examined the characteristics of KCNQ2 variants.Methods: KCNQ2 pathogenic variants were collected from in‐house data and two large disease databases with their clinical phenotypes. Nonpathogenic KCNQ2 variants were collected from the Genome Aggregation Database (gnomAD). Pathogenicity of all variants was reevaluated with clinical information to exclude irrelevant variants. The cumulative distribution plots of B(F)NE, KCNQ2 DEE, and gnomAD KCNQ2 variants were compared. Several algorithms predicting genetic variant pathogenicity were evaluated.Results: A total of 259 individuals or pedigrees with 216 different pathogenic KCNQ2 variants and 2967 individuals with 247 different nonpathogenic variants were deemed eligible for the study. Compared to the distribution of nonpathogenic variants, B(F)NE and KCNQ2 DEE missense variants occurred in five and three specific KCNQ2 regions, respectively. Comparison between B(F)NE and KCNQ2 DEE sets showed that B(F)NE missense variants frequently localized to the intracellular domain between S2 and S3, whereas those of KCNQ2 DEE were more frequent in S6, and its adjacent pore domain, as well as in the intracellular domain between S6 and helix A. The scores of Protein Variation Effect Analyzer (PROVEAN) and Percent Accepted Mutation (PAM) 30 prediction algorithms were associated with phenotypes of the variant loci.Significance: Missense variants in the intracellular domain between S2 and S3 are likely to cause B(F)NE, whereas those in S6 and its adjacent regions are more likely to cause KCNQ2 DEE. With such regional specificities of variants, PAM30 is a helpful tool to examine the possibility that a novel KCNQ2 variant is a B(F)NE or KCNQ2 DEE variant in genetic analysis.
Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy
Objective: Pathogenic variants of KCNQ2, which encode a potassium channel subunit, cause either benign (familial) neonatal epilepsy—B(F)NE)—or KCNQ2 encephalopathy (KCNQ2 DEE). We examined the characteristics of KCNQ2 variants.Methods: KCNQ2 pathogenic variants were collected from in‐house data and two large disease databases with their clinical phenotypes. Nonpathogenic KCNQ2 variants were collected from the Genome Aggregation Database (gnomAD). Pathogenicity of all variants was reevaluated with clinical information to exclude irrelevant variants. The cumulative distribution plots of B(F)NE, KCNQ2 DEE, and gnomAD KCNQ2 variants were compared. Several algorithms predicting genetic variant pathogenicity were evaluated.Results: A total of 259 individuals or pedigrees with 216 different pathogenic KCNQ2 variants and 2967 individuals with 247 different nonpathogenic variants were deemed eligible for the study. Compared to the distribution of nonpathogenic variants, B(F)NE and KCNQ2 DEE missense variants occurred in five and three specific KCNQ2 regions, respectively. Comparison between B(F)NE and KCNQ2 DEE sets showed that B(F)NE missense variants frequently localized to the intracellular domain between S2 and S3, whereas those of KCNQ2 DEE were more frequent in S6, and its adjacent pore domain, as well as in the intracellular domain between S6 and helix A. The scores of Protein Variation Effect Analyzer (PROVEAN) and Percent Accepted Mutation (PAM) 30 prediction algorithms were associated with phenotypes of the variant loci.Significance: Missense variants in the intracellular domain between S2 and S3 are likely to cause B(F)NE, whereas those in S6 and its adjacent regions are more likely to cause KCNQ2 DEE. With such regional specificities of variants, PAM30 is a helpful tool to examine the possibility that a novel KCNQ2 variant is a B(F)NE or KCNQ2 DEE variant in genetic analysis.
- 1 February 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 65, 118-123
Different types of suppression-burst patterns in patients with epilepsy of infancy with migrating focal seizures (EIMFS)
- 1 February 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 65, 118-123
Different types of suppression-burst patterns in patients with epilepsy of infancy with migrating focal seizures (EIMFS)